Who Generates Higher Gross Profit? Biogen Inc. or Ligand Pharmaceuticals Incorporated

Biogen Inc. vs. Ligand Pharmaceuticals: A Decade of Gross Profit Analysis

In the competitive landscape of biotechnology, understanding which companies lead in profitability is crucial. Over the past decade, Biogen Inc. has consistently outperformed Ligand Pharmaceuticals Incorporated in terms of gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching approximately 12.4 billion, while Ligand's highest was around 245 million in 2018. This stark contrast highlights Biogen's dominant market position, generating nearly 75 times more profit than Ligand on average.

Biogen's gross profit saw a decline post-2019, dropping to about 7.3 billion by 2023, reflecting a 41% decrease. Meanwhile, Ligand's profits remained relatively stable, with minor fluctuations. This data underscores the resilience of smaller firms like Ligand amidst industry giants. Investors and stakeholders should consider these trends when evaluating potential growth and stability in the biotech sector.